Contagion Live: Targeting Lung Blood Vessel Inflammation in COVID-19 Patients
UC cardiologist discusses use of razuprotafib to lessen blood vessel inflammation
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients. Becker, also a UC Health cardiologist, and Duncan Hite, a professor in the UC College of Medicine, and medical director of critical care at UC Health, are overseeing the trial using razuprotafib at UC. The drug is being used as a part of clinical trial in 20 sites across the nation.
Listen to the Contagion Live interview online.
Learn more about the research involving Dr. Becker and Dr. Hite.
Related Stories
Yahoo! News promotes UC botanist's solution for honeysuckle
February 10, 2026
Yahoo! News shared University of Cincinnati botanist Denis Conover's method for eliminating honeysuckle without using chemicals.
University of Cincinnati Cancer Center names David Gius, MD, PhD, as director
February 10, 2026
Following a highly competitive national search, the University of Cincinnati Cancer Center has appointed David Gius, MD, PhD, as its next director.
Breakthrough UC study sheds light on survival of new neurons in adult brain
February 9, 2026
Research from the University of Cincinnati College of Medicine, recently published in the journal Nature Communications, is revealing how immune cells in the adult brain regulate the generation of new neurons.